Patty Hildreth
Family · Audubon, IANPI 1679573893
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 387 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,904, 3.1 times the $606 reported in 2021. Among family clinicians in IA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 387 payments — averaging $17.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$800
- Alkermes, Inc.$778
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$732
- Teva Pharmaceuticals USA, Inc.$601
- Lundbeck LLC$544
- Neurocrine Biosciences, Inc.$517
- plus $3K from 14 others
What the payments were for
- Food & beverage$6,646100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 48 | $800 |
| Alkermes, Inc. | 51 | $778 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $732 |
| Teva Pharmaceuticals USA, Inc. | 43 | $601 |
| Lundbeck LLC | 29 | $544 |
| Neurocrine Biosciences, Inc. | 42 | $517 |
| Vanda Pharmaceuticals Inc. | 17 | $491 |
| Supernus Pharmaceuticals, Inc. | 27 | $435 |
| AbbVie | 23 | $382 |
| Corium, LLC | 14 | $313 |
| Almatica Pharma LLC | 16 | $304 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $280 |
| Johnson & Johnson | 7 | $158 |
| E.r. Squibb & Sons, L.L.C. | 5 | $99 |
| Axsome Therapeutics, Inc. | 2 | $59 |
| Tris Pharma Inc | 2 | $43 |
| Collegium Pharmaceutical, Inc. | 3 | $43 |
| Noven Therapeutics, LLC | 2 | $35 |
| Indivior Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$184
How this compares
$6,646 in reported general payments places this provider in the 95th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 30 | $258,383 |
| IngrezzaValbenazine Tosylate | 29 | $238,953 |
| VraylarCariprazine Hcl | 54 | $86,929 |
| RexultiBrexpiprazole | 79 | $82,826 |
| LybalviOlanzapine/Samidorphan Malate | 48 | $76,844 |
| CaplytaLumateperone Tosylate | 47 | $71,255 |
| TrintellixVortioxetine Hydrobromide | 73 | $44,353 |
| Abilify MaintenaAripiprazole | 14 | $38,742 |
| Lurasidone Hcl | 37 | $16,473 |
| VyvanseLisdexamfetamine Dimesylate | 26 | $9,907 |
| QelbreeViloxazine Hcl | 12 | $8,405 |
| ViibrydVilazodone Hcl | 26 | $7,825 |
| Clozapine | 92 | $7,013 |
| QuviviqDaridorexant Hcl | 12 | $6,765 |
| Methylphenidate ErMethylphenidate Hcl | 35 | $6,541 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $601 | $258,38330 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $517 | $238,95329 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $800 | $121,56993 claims |
| AbbVieVraylar, Viibryd | $382 | $94,75480 claims |
| Alkermes, Inc.Lybalvi | $778 | $76,84448 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $732 | $71,25547 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $280 | $54,26099 claims |
| Supernus Pharmaceuticals, Inc.Qelbree | $435 | $8,40512 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $15 | $6,76512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,268 family providers in Iowa.
Other family in Audubon
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.